BioQ Pharma Expands U.S. License and Supply Agreement to Commercialize Third Ready-to-Use Infusion Product

SAN FRANCISCO, April 28, 2016 (GLOBE NEWSWIRE) — BioQ Pharma Incorporated, a specialty pharmaceutical company, today announced the expansion of its license and supply agreement with Sandoz, a division of Novartis, under which Sandoz now has the right to exclusively market an additional ready‐to‐use BioQ Pharma infusion pharmaceutical in the United States. Under the agreement, BioQ Pharma is responsible for developing and supplying the unit‐dose infusion pharmaceutical, and Sandoz is responsible for obtaining regulatory approval, marketing and commercializing the product.

“We are pleased to grow our relationship with Sandoz, a leader in the pharmaceutical industry, with the addition of a third infusion product to our previously announced agreement. We believe that the presentation of this infusion pharmaceutical, AS-2, may provide important benefits for patients requiring sedation. Additionally, we believe that BioQ Pharma’s ready-to-use infusion system adds value by helping to lower the total cost of drug delivery,” said Josh Kriesel, President and CEO of BioQ Pharma.
About BioQ Pharma
BioQ Pharma is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company’s infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma’s vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company’s proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma’s commercial collaborators and strategic partners include Novartis’ Sandoz unit, Cipla, Lunatus, Lee’s Pharmaceutical, and West Pharmaceutical Services.

Company Contact Information:
Josh Kriesel
President and CEO
415-336-6496
Ron Pauli
Chief Financial Officer
415-889-7707
Media:
Stephanie Carrington
Integrated Corporate Relations, Inc. (ICR)
646-277-1282